Your browser is no longer supported. Please, upgrade your browser.
AIMT Aimmune Therapeutics, Inc. daily Stock Chart
AIMT [NASD]
Aimmune Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.87 Insider Own0.10% Shs Outstand63.88M Perf Week5.56%
Market Cap2.00B Forward P/E- EPS next Y-3.43 Insider Trans-22.88% Shs Float46.33M Perf Month13.53%
Income-238.60M PEG- EPS next Q-1.05 Inst Own92.90% Short Float23.61% Perf Quarter34.80%
Sales- P/S- EPS this Y-77.20% Inst Trans6.83% Short Ratio11.31 Perf Half Y56.50%
Book/sh2.44 P/B12.83 EPS next Y13.60% ROA-77.50% Target Price48.30 Perf Year33.65%
Cash/sh3.06 P/C10.23 EPS next 5Y34.60% ROE-104.50% 52W Range16.95 - 32.22 Perf YTD30.85%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-2.86% Beta-0.06
Dividend %- Quick Ratio4.60 Sales past 5Y- Gross Margin- 52W Low84.66% ATR1.14
Employees261 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)65.67 Volatility4.60% 3.65%
OptionableYes Debt/Eq0.26 EPS Q/Q-16.00% Profit Margin- Rel Volume0.89 Prev Close31.59
ShortableYes LT Debt/Eq0.26 EarningsNov 06 AMC Payout- Avg Volume966.93K Price31.30
Recom2.00 SMA2010.27% SMA5015.18% SMA20039.37% Volume859,738 Change-0.92%
Dec-13-19Downgrade Credit Suisse Outperform → Neutral $30
Jul-12-19Resumed ROTH Capital Buy $45
May-21-19Resumed Credit Suisse Outperform $36 → $30
Dec-13-18Initiated Goldman Neutral $32
May-18-18Resumed Piper Jaffray Overweight
Feb-07-18Initiated RBC Capital Mkts Outperform $55
Dec-21-17Initiated Robert W. Baird Outperform $64
Nov-20-17Initiated ROTH Capital Buy
Sep-26-16Initiated JMP Securities Mkt Outperform
Mar-01-16Initiated Wedbush Outperform $42
Nov-17-15Reiterated Piper Jaffray Overweight $35 → $38
Aug-31-15Initiated Piper Jaffray Overweight $35
Aug-31-15Initiated Credit Suisse Outperform $44
Aug-31-15Initiated BofA/Merrill Buy $36
Dec-08-19 06:24PM  Do Hedge Funds Love Aimmune Therapeutics Inc (AIMT) ? Insider Monkey
Nov-15-19 04:05PM  Aimmune to Participate in Three Upcoming Investor Conferences Business Wire
Nov-14-19 10:03PM  Edited Transcript of AIMT earnings conference call or presentation 6-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-08-19 11:00AM  Quality of Life Outcomes from Two New Surveys Highlight Emotional Impact of Peanut Allergy and Need for New Treatments Business Wire
11:00AM  New Data Presented at ACAAI 2019 Show Importance of Clinical History in Identifying AR101-Eligibile Patients for PALISADE Study without a Food Challenge Business Wire
07:00AM  New Real-World Data Unveiled at ACAAI Indicates Comparable Clinical Practice Logistics to Implement Oral Immunotherapy and Environmental Allergy Shots Business Wire
07:00AM  AR101 Demonstrates Consistent Efficacy and Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical Data Business Wire
Nov-06-19 04:05PM  Aimmune Therapeutics Announces Third Quarter 2019 Financial Results and Provides Operational Highlights Business Wire
08:21AM  The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings Benzinga
Nov-04-19 04:05PM  Aimmune to Participate in the Credit Suisse 28th Annual Healthcare Conference Business Wire
Oct-31-19 07:00AM  Aimmune to Present New Data on Safety and Efficacy of AR101, Clinical Practice Implementation of Oral Immunotherapy, Quality of Life and Other Related Studies at ACAAI 2019 Business Wire
Oct-30-19 07:00AM  Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Recent Operational Highlights Business Wire
Oct-28-19 10:59AM  Here is What Hedge Funds Think About Aimmune Therapeutics Inc (AIMT) Insider Monkey
Oct-24-19 04:55PM  Najarian Brothers Highlight Unusual Options Activity In Activision Blizzard, Cronos Group Benzinga
Oct-07-19 06:48AM  My Stock of the Week Is Aimmune Therapeutics TheStreet.com
Oct-03-19 01:24AM  Edited Transcript of AIMT earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Sep-26-19 07:00AM  Aimmune to Present at the Cantor Global Healthcare Conference Business Wire
Sep-18-19 10:33AM  Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More Zacks
Sep-16-19 04:19PM  Analyst: DBV's Peanut Allergy Drug Could Outscore Aimmune's On Safety Front Benzinga -5.88%
04:16PM  Profit-Takers Drag This Highflying Biotech Stock Into The Red Investor's Business Daily
01:18PM  Aimmune's Peanut Allergy Drug Gets FDA Committee's Support Zacks
01:15PM  A Look At Benzinga Pro's Most-Searched Tickers For September 16, 2019 Benzinga
Sep-13-19 08:00PM  A Mixed FDA Panel Just Recommended This Biotech's Peanut Allergy Drug Investor's Business Daily
05:53PM  FDA Allergenic Products Advisory Committee Votes to Support the Use of Aimmunes PALFORZIA (AR101) for Peanut Allergy Business Wire
05:10PM  A Mixed FDA Panel Just Recommended This Biotech's Peanut Allergy Drug Investor's Business Daily
04:47PM  First peanut allergy therapy gets backing from U.S. regulators' expert advisers Reuters
10:30AM  Aimmune's stock halted as FDA panel's decision awaited on peanut allergy treatment MarketWatch
07:05AM  Aimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting to Discuss PALFORZIA (AR101) for Peanut Allergy Business Wire
06:50AM  Aimmune Stock Halted as FDA Considers Peanut Allergy Treatment TheStreet.com
Sep-11-19 04:18PM  This Biotech Just Hit A 6-Month High; FDA Panel To Consider Allergy Med Investor's Business Daily +15.41%
Sep-10-19 04:37PM  Biotech Stock On The Radar: Aimmune Awaits Adcom Test Benzinga +11.58%
09:40AM  If You're Not Allergic to Risk, Consider Aimmune Therapeutics on Strength TheStreet.com
Sep-09-19 10:23AM  Peanut Allergy Drug Faces Next Test at Key FDA Panel Meeting Bloomberg
09:31AM  3 Biotech Stocks That Could Soar This Week Motley Fool
Sep-05-19 10:12AM  3 Strong Buy Biotech Stocks Ahead of FDA Verdicts SmarterAnalyst +7.67%
Aug-28-19 07:00AM  Aimmune to Participate in Three Investor Conferences in September Business Wire
Aug-26-19 08:54AM  Implied Volatility Surging for Aimmune (AIMT) Stock Options Zacks
Aug-21-19 07:40AM  The Daily Biotech Pulse: Ra Pharma Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform Benzinga
07:00AM  Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for Egg Allergy Business Wire
Aug-14-19 06:15PM  3 Top Biotech Stocks to Buy in August Motley Fool
Aug-09-19 06:54PM  Aimmune Therapeutics, Inc. (AIMT) Q2 2019 Earnings Call Transcript Motley Fool
Aug-08-19 04:05PM  Aimmune Therapeutics Announces Second Quarter 2019 Financial Results and Provides Operational Highlights Business Wire
09:53AM  DBV Resubmits Regulatory Application For Peanut Allergy Drug, Stock Rallies Benzinga
Aug-06-19 07:00AM  Aimmune to Present at the Wedbush PacGrow Healthcare Conference Business Wire
Jul-12-19 09:47AM  Aimmune Down on Negative ICER Review on Allergy Candidate Zacks
07:24AM  The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study Benzinga
Jul-11-19 06:51PM  Here's Why Aimmune Therapeutics Fell 7% Today Motley Fool -6.94%
08:01AM  Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final Report on AR101 for Peanut Allergy Business Wire
Jul-01-19 03:27PM  Edited Transcript of AIMT earnings conference call or presentation 8-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-28-19 07:00AM  Aimmune Submits Marketing Authorization Application to European Medicines Agency for AR101 for Peanut Allergy Business Wire
Jun-25-19 10:18AM  Heres What Hedge Funds Think About Aimmune Therapeutics Inc (AIMT) Insider Monkey
Jun-20-19 09:22AM  Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Is Expected To Breakeven Simply Wall St.
Jun-13-19 09:00AM  What Makes Aimmune Therapeutics (AIMT) a New Buy Stock Zacks
Jun-12-19 08:00AM  Aimmune to Present at the JMP Securities Life Sciences Conference Business Wire
Jun-11-19 08:00AM  Aimmune Therapeutics Discusses AR101s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting Business Wire
Jun-05-19 08:00AM  Aimmune to Participate in the Goldman Sachs 40th Annual Healthcare Conference Business Wire
Jun-04-19 10:01AM  Data from Two Studies Confirm Quality of Life and Psychosocial Burden of Living with Peanut Allergy Business Wire
07:01AM  New Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year Business Wire
Jun-02-19 07:01AM  Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy Business Wire
May-24-19 08:00AM  Aimmune to Present AR101 Data at European Academy of Allergy and Clinical Immunology 2019 Congress Business Wire
May-21-19 04:01PM  New Study Shows More Than Half of Teens with Peanut Allergy Visited the E.R., More Than One-Third Required Hospitalization Due to Accidental Exposure to Peanut Business Wire
May-19-19 07:00AM  Top 5 New Drug Launches of 2019 -- and the Biotech Stocks That Could Win Big Motley Fool
May-16-19 08:30AM  Aimmune to Present at RBC Capital Markets Global Healthcare Conference Business Wire
08:00AM  Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy Business Wire
May-08-19 11:00PM  Aimmune Therapeutics, Inc. (AIMT) Q1 2019 Earnings Call Transcript Motley Fool
04:13PM  Aimmune Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Aimmune Therapeutics Announces First Quarter 2019 Financial Results and Provides Operational Highlights Business Wire
May-02-19 11:59AM  Heres What Hedge Funds Think About Aimmune Therapeutics Inc (AIMT) Insider Monkey
May-01-19 08:00AM  Aimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results and Recent Operational Highlights Business Wire
Apr-03-19 08:00AM  Aimmune Therapeutics to Present at 18th Annual Needham & Company Healthcare Conference Business Wire
Mar-25-19 04:26PM  Peninsula biotech lines up chance to crack the peanut allergy nut American City Business Journals
08:00AM  European Phase 3 Trial of Aimmune Therapeutics AR101 Meets Primary Endpoint Business Wire
Mar-24-19 06:33PM  4 Blockbuster Drug Launches to Watch in 2019 Motley Fool
Mar-21-19 08:19AM  Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus Zacks
Mar-20-19 03:25PM  NASH, Allergies and Beauty Stocks: Invest or Not? Zacks
Mar-18-19 08:00AM  U.S. FDA Accepts BLA Filing of Aimmune Therapeutics AR101 for Peanut Allergy Business Wire
Mar-07-19 12:03AM  Edited Transcript of AIMT earnings conference call or presentation 28-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
Mar-05-19 08:15AM  Detailed Research: Economic Perspectives on Canopy Growth, Aimmune Therapeutics, Nektar Therapeutics, Workday, Workiva, and MAG Silver What Drives Growth in Today's Competitive Landscape GlobeNewswire
08:00AM  Aimmune Therapeutics to Participate in Three Investor Conferences in March Business Wire
Feb-28-19 04:01PM  Aimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational Highlights Business Wire
Feb-25-19 08:00AM  Aimmune Therapeutics Presents New AR101 Data at AAAAI, Including Demonstrated Reduction in Accidental Exposures to Peanut Requiring Treatment Business Wire
Feb-21-19 08:00AM  Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights Business Wire
Feb-19-19 02:34PM  Trading Notes for Select Stocks TheStreet.com
Feb-04-19 10:33AM  Aimmune Therapeutics to Present AR101, OIT and Peanut Allergy Data at 2019 AAAAI Annual Meeting Business Wire
Feb-01-19 09:48AM  6 Biotech Stocks to Watch Now Motley Fool
Jan-29-19 09:30PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Jan-22-19 06:01AM  3 Biotech Stocks That Could Be Slapped by the U.S. Government Shutdown Motley Fool
Jan-19-19 08:03AM  3 Potential New Drugs Held Up by the Shutdown Motley Fool
Jan-18-19 08:00AM  Aimmune Therapeutics Appoints Andrew Oxtoby as Chief Commercial Officer Business Wire
Jan-15-19 07:55AM  Today's Research Reports on Trending Tickers: Aimmune Therapeutics and Mirati Therapeutics ACCESSWIRE
07:22AM  Jim Cramer Shares His Thoughts On Alibaba, Dynavax, Starbucks And More Benzinga
Jan-14-19 06:50PM  Cramer's lightning round: The way to play Goldman's downgrade of Starbucks CNBC -5.19%
Jan-08-19 11:30AM  This Under-the-Radar Biotech Stock Is My Top Pick for 2019 TheStreet.com
Jan-04-19 08:45AM  Aimmune Therapeutics and KKR Enter into $170M Loan Agreement to Fund AR101 Commercialization and Pipeline Advancement Business Wire
Jan-03-19 07:35AM  Investor Expectations to Drive Momentum within L3 Technologies, The Goldman Sachs Group, Genuine Parts, Bruker, Omeros, and Aimmune Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Jan-02-19 08:00AM  Aimmune Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7th Business Wire
Dec-21-18 04:01PM  Aimmune Therapeutics Submits BLA to FDA for AR101 for the Treatment of Peanut Allergy in Children and Adolescents Ages 417 Business Wire -9.25%
Dec-20-18 04:32PM  Why Tilray, Fortuna Silver Mines, and Aimmune Therapeutics Jumped Today Motley Fool +15.48%
01:05PM  These 4 Biotech Stocks are Picking Up Speed ACCESSWIRE
11:19AM  Delay for Peanut Allergy Drug Sinks Biotech Stock Bloomberg
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ADELMAN DANIEL C MDChief Medical OfficerDec 09Option Exercise11.4520,000229,00041,250Dec 11 05:50 PM
ADELMAN DANIEL C MDChief Medical OfficerDec 09Sale30.0420,000600,71621,250Dec 11 05:50 PM
BJERKHOLT ERICChief Financial OfficerSep 18Buy22.571,55034,97733,574Sep 20 08:55 AM